Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Treating the Root Cause of Acute Cannabinoid Intoxication with Simon Allen Anebulo Pharmaceuticals TRANSCRIPT
Download PDFJun 30, 2023
Simon Allen is the CEO and Director of Anebulo Pharmaceuticals, which focuses on finding an effective treatment for acute cannabinoid intoxication or ACI, particularly in an emergency department setting. ACI is a condition where an individual has consumed or smoked too much cannabis or products that contain THC or synthetic cannabis and is experiencing symptoms of psychosis, anxiety, elevated heart rate, or is unresponsive. Their drug ANEB-001 is designed to address the cause of the symptoms without the need for traditional methods like benzodiazepines and beta blockers, which have their risks.
Simon explains, "What we are seeing is individuals taking these high-potency edibles, for example, and also smoking and vaping. These are other forms that can create ACI outcomes. And essentially, they're out for several hours, if not overnight, in the hospital. This can get as serious as the escalation to a psychiatric ward if the individual is so psychotic, agitated, and anxious that the emergency department can't handle it or chooses not to handle it and pushes it to the psychiatric ward. And those expenses are in the tens of thousands of dollars to the healthcare system. Not only that, there are extremely poor patient outcomes."
"What's important is that these molecules, the synthetic ones, are, unfortunately extremely strong binders to the CB1 receptor and do more to stimulate effectively. And very, very small doses of these synthetic cannabinoids can create very poor patient outcomes simply because they're much tighter binders to the CB1 receptor compared to THC. And when they do bind to that receptor, they're much more active. And so the street names like K2 and Spice are examples."
@AnebuloP #AnebuloPharmaceuticals #ACI #AcuteCannabinoidIntoxication #Cannabis #Overdose
